Latest filing published 01 Mar 2021 for Karyopharm Therapeutics Inc..
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
John Demaree: trading record in brief
Filings by John Demaree span 2 companies, the busiest being Karyopharm Therapeutics Inc. and G1 Therapeutics, Inc. The record holds 3 filings, for trades running from 10 December 2018 to 25 February 2021.
No open-market sale appears; the market trades are 2 purchases worth €121k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 1 share grant.
On 1 March 2021 came the latest disclosure, a share grant in Karyopharm Therapeutics Inc. The last insider purchase was made public on 27 August 2020, 2,265 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to John Demaree
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 15,849 shares0Common StockSEC:0001209191-21-015483:0
- 7,500 shares@ US$14.54Common StockSEC:0001209191-20-048515:0Canonical exit: 24 Nov 2020 (T+90)
- 1,000 shares@ US$33.15100.0% of flowCommon StockSEC:0001562180-18-004904:0Canonical exit: 10 Mar 2019 (T+90)
3 of 3 declarations
